Skip to main content
DYAI
NASDAQ Life Sciences

Dyadic Q2 2026: Revenue Holds Steady, but Losses Deepen and a Going Concern Warning Clouds the Outlook

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$1
Mkt Cap
$38.261M
52W Low
$0.655
52W High
$1.6
52W Position info
53% above low
Off High info
38% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

DYAI sits 53% above its 52-week low of $0.655.

Summary

Dyadic's Q2 2026 results show flat revenue and a widening net loss, with management issuing a going concern warning as cash dwindles to $4.79 million. Commercialization is accelerating, but survival hinges on near-term capital raising.


Key Events · Earnings and Guidance · DYAI

  • Going Concern Warning Issued

    Management concluded there is substantial doubt about Dyadic's ability to continue as a going concern for the 12 months following June 30, 2026, citing a history of net losses and a cash position of only $4.79 million.

  • Q2 Net Loss Widens to $2.12M

    Net loss increased 18.4% year-over-year to $2,123,884, or $0.06 per share, driven by higher cost of revenue and G&A expenses, despite flat total revenue of $961,138.

  • Cash Burn Accelerates

    Cash, equivalents, restricted cash, and investment securities fell to $4.79 million as of June 30, 2026, from $8.59 million at December 31, 2025 — a burn rate of approximately $1.9 million per quarter.

  • Commercialization Gains Momentum

    Dyadic shipped six recombinant protein products, initiated pilot sales for cultivated-meat applications, and saw partners Proliant, Fermbox, and Inzymes begin commercial sales or scale-up, signaling early revenue diversification.


Analysis · DYAI · Life Sciences

Dyadic's Q2 2026 revenue came in at $961,138, essentially flat year-over-year, yet the net loss widened to $2.12 million from $1.79 million. Cash reserves dwindled to $4.79 million as of June 30, 2026, down from $8.59 million at year-end 2025. Management explicitly flagged substantial doubt about the company's ability to continue as a going concern for the next 12 months — a critical red flag for a micro-cap biotech already under Nasdaq delisting pressure. On the positive side, the company highlighted accelerating commercialization with six recombinant protein products shipped, initial pilot sales for cultivated-meat applications, and progress across multiple partnerships (Proliant, Fermbox, Inzymes). The C1 platform demonstrated rapid pandemic response capabilities, producing ebolavirus antigens in ~15 days. However, the going concern warning and cash burn rate overshadow the operational progress, making this a high-stakes earnings report.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DYAI was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.3M. The 52-week trading range was $0.65 to $1.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DYAI - Latest Insights

DYAI
Nov 13, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.327
Real-time Price: $0.350 info
Change: +$0.023 (+7%) info
Market Cap: $13.101M info
DYAI
Nov 12, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.3501
Real-time Price: $0.350 info
Change: -$0.0001 (-0.03%) info
Market Cap: $13.101M info
DYAI
Sep 25, 2026, 5:27 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.4198
Real-time Price: $0.350 info
Change: -$0.0698 (-17%) info
Market Cap: $13.101M info
DYAI
Aug 17, 2026, 7:27 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.710
Real-time Price: $0.350 info
Change: -$0.360 (-51%) info
Market Cap: $13.101M info
DYAI
Aug 14, 2026, 9:17 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7702
Real-time Price: $0.350 info
Change: -$0.4202 (-55%) info
Market Cap: $13.101M info